CONFERENCE PROGRAMS

Cambridge Healthtech Institute’s 13th Annual

Immunogenicity Assessment & Clinical Relevance

Assay Strategy for Meaningful Evaluation

October 20-21, 2021 - IN-PERSON & ONLINE


This year's Immunogenicity Summit brings the FDA together with leading industry and academic experts to discuss the development, application and validation of immunogenicity assays. Learn how to manage drug and target interference and tolerance, understand the impact of pre-existing antibodies and interpret the clinical significance of assay data. Novel modalities including cell and gene therapies are posing new challenges to the industry, all of which will be discussed in-depth at this meeting.

View Program


Cambridge Healthtech Institute ’s 13th Annual

Immunogenicity Prediction & Control

Regulatory Perspectives, Risk Factors, and Management

October 21-22, 2021 - IN-PERSON & ONLINE


The impact of immunogenicity on safety and efficacy, and consequent cost to the industry, is well understood. Accordingly, investigators are focusing on factors that contribute to immunogenicity, as well as a number of different approaches to predict immunogenicity at the drug discovery stage. There are several major problematic areas with novel modalities. Efforts are being made to suppress immune responses to these products and to introduce tolerizing and deimmunization approaches. Attend in 2021 to hear insightful feedback from the FDA and learn from top industry and academics in this field.

View Program


Cambridge Healthtech Institute’s 9th Annual

Optimizing Bioassays for Biologics

Case Studies Demonstrating Successful Bioassay Development

October 21-22, 2021 - IN-PERSON & ONLINE

New therapeutic modalities, including cell & gene therapies, immunotherapies, and antibody therapies, continue to push the limit on bioassay development and implementation. New formats present challenges including determining what reference materials to use and how to validate the assay. Health authorities and USP have provided guidance for the design and validation of a bioassay; however, they are just starting to consider solutions to common problems springing from this revolution in technology. Cambridge Healthtech Insitute's 9th Annual Optimizing Bioassays for Biologics will bring together leaders working in bioanalytical and bioassay development to present case studies and best practices for handling the most common issues in biological assay development, validation, transfer, and maintenance.   be presented along with recommendations for implementation to ensure a steady drug development pipeline.

View Program


Cambridge Healthtech Institute’s 13th Annual

Symposium: Immunology for Biotherapeutics

Understanding and Manipulating the Immune System for Therapeutic Advantage

October 19, 2021 - IN-PERSON & ONLINE


Many of the exciting developments in drug discovery and development today concern the immune response and its manipulation and control. Our understanding of immune involvement in therapeutic disorders and their treatment is developing rapidly. T and B lymphocyte subsets, innate lymphoid cells (ILCs), macrophages, dendritic cells and cytokines are all involved in a complex manner. There is the potential for manipulation for therapeutic advantage, yet the danger disastrous consequences if not well understood. At this virtual symposium, attendees will find out how to utilize the immune system and overcome inhibitory factors without overlooking potential safety issues.

View Program


Training Seminar: Introduction to Bioassay Design

October 20-21, 2021 - IN-PERSON & ONLINE


The training seminar will be held prior to the start of the Optimizing Bioassays for Biologics conference.

View Program

 


Register